Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Reset Your Password
We will email you instructions to reset your
Background and Aims: The use of continuous subcutaneous insulin infusion (CSII) has demonstrated fewer acute complications in patients with type 1 diabetes (T1D). This study aims to examine the frequency of adverse clinical outcomes among T1D patients who tested positive for COVID‐19 and were users versus non‐users of insulin pump therapy.
Methods: The analysis included 241 T1D patients from the T1DX‐QI COVID‐19 registry who tested positive for COVID‐19. Healthcare providers extracted patient data from electronic medical records of 52 endocrinology clinics across the U.S. Data was collected from April 2020 to September 2020.
Results: In this population, 38% (N = 92) of T1D patients were insulin pump users, whereas 62% (N = 149) were non‐users. HbA1c levels in the insulin pump group were lower compared to non‐users (Median [IQR], %: 8.0 [1.9] vs. 9.8 [3.7] [p < 0.001]). Adverse events, such as diabetic ketoacidosis, were less frequently recorded for insulin pump users relative to the non‐users (9% vs.30%) [p < 0.001]. Further, patients who did not use insulin pump therapy were more likely to be hospitalized (29% vs.12%) [p < 0.001] or need ICU care [25% vs.4%) [p < 0.001] than patients who used insulin pumps.
Full study abstract listed under number O078 at this link: https://www.liebertpub.com/doi/10.1089/dia.2021.2525.abstracts
This site uses Akismet to reduce spam. Learn how your comment data is processed.